Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO)
- PMID: 29256181
- DOI: 10.1007/s40618-017-0809-5
Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO)
Abstract
Background: Oxidative stress is involved in the pathogenesis of Graves' orbitopathy (GO) and several antioxidant agents, namely, selenium, quercetin, enalapril, vitamin C, N-acetyl-L-cysteine, and melatonin, have been shown to reduce oxidative stress and its consequences in primary culture of orbital fibroblasts. In addition, selenium is effective for the treatment of mild GO. Here, we investigated the action of three additional antioxidants in orbital fibroblasts, namely, retinol, β-carotene, and vitamin E.
Methods: Primary cultures of orbital fibroblasts were established from GO patients and control subjects. To induce oxidative stress, cells were treated with H2O2, after which glutathione disulfide (GSSG) (a parameter of oxidative stress), cell proliferation, hyaluronic acid, TNFα, IFNγ, and IL1β were measured.
Results: H2O2-dependent oxidative stress (augmented GSSG) was associated with increased cell proliferation and cytokine release. All the three antioxidant substances reduced GSSG in both GO and control fibroblasts. β-carotene reduced proliferation in GO, but not in control fibroblasts. IL1β was reduced by all three substances. Retinol reduced IFNγ in GO and control fibroblasts.
Conclusions: Our study supports an antioxidant role of retinol, β-carotene, and vitamin E in orbital fibroblasts from patients with GO and provides a basis for a possible clinical use these substances.
Keywords: Antioxidant; Fibroblast; Graves’; Ophthalmopathy; Orbitopathy; Retinol; Vitamin E; β-Carotene.
Similar articles
-
Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?J Endocrinol Invest. 2018 Feb;41(2):193-201. doi: 10.1007/s40618-017-0718-7. Epub 2017 Jun 27. J Endocrinol Invest. 2018. PMID: 28656526
-
Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy.Thyroid. 2017 Feb;27(2):271-278. doi: 10.1089/thy.2016.0397. Epub 2016 Dec 16. Thyroid. 2017. PMID: 27824294
-
The protective effect of antioxidants on orbital fibroblasts from patients with Graves' ophthalmopathy in response to oxidative stress.Mol Vis. 2013 Apr 16;19:927-34. Print 2013. Mol Vis. 2013. PMID: 23687429 Free PMC article.
-
Antioxidant Therapy in Graves' Orbitopathy.Front Endocrinol (Lausanne). 2020 Dec 14;11:608733. doi: 10.3389/fendo.2020.608733. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33381085 Free PMC article. Review.
-
Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.Exp Eye Res. 2016 Jan;142:83-91. doi: 10.1016/j.exer.2015.02.007. Exp Eye Res. 2016. PMID: 26675405 Review.
Cited by
-
Role of genetics and epigenetics in Graves' orbitopathy.Eur Thyroid J. 2024 Nov 6;13(6):e240179. doi: 10.1530/ETJ-24-0179. Print 2024 Dec 1. Eur Thyroid J. 2024. PMID: 39378053 Free PMC article. Review.
-
Oxidative Stress in Graves Disease and Graves Orbitopathy.Eur Thyroid J. 2020 Dec;9(Suppl 1):40-50. doi: 10.1159/000509615. Epub 2020 Nov 20. Eur Thyroid J. 2020. PMID: 33511084 Free PMC article.
-
Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.J Endocrinol Invest. 2020 Apr;43(4):401-411. doi: 10.1007/s40618-019-01141-3. Epub 2019 Nov 5. J Endocrinol Invest. 2020. PMID: 31691261 Review.
-
Simple Electrospinning Method for Biocompatible Polycaprolactone β-Carotene Scaffolds: Advantages and Limitations.Polymers (Basel). 2024 May 11;16(10):1371. doi: 10.3390/polym16101371. Polymers (Basel). 2024. PMID: 38794563 Free PMC article.
-
Epac1 Inhibits Orbital Fibroblast Activation to Ameliorate Thyroid-Associated Orbitopathy-Like Features Through the JAK/STAT Signaling Pathway.Invest Ophthalmol Vis Sci. 2025 Jul 1;66(9):68. doi: 10.1167/iovs.66.9.68. Invest Ophthalmol Vis Sci. 2025. PMID: 40736178 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical